C-РЕАКТИВНЫЙ БЕЛОК




А. В. Наумов, Л. Т. Арцименя, Е. Ю. Биндич, Н. В. Наумова

Аннотация


Приведен обзор современной литературы о важном клиническом биомаркёре воспаления и представителе белков острой фазы С-реактивном белке. Роли его пентамерной (pCRP) и мономерной (mCRP) форм. Рассмотрены механизмы, лежащие в основе воспалительной реакции и патофизиологические доказательства использования его в качестве маркёра и прогностического фактора различных заболеваний.

Ключевые слова


С-реактивный белок

Полный текст:

Литература


Agrawal, A. Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter / A. Agrawal, D. Samols , I. Kushner // Mol. Immunol. – 2003. – Vol. 40. – № 6. – P. 373-380.

Agrawal, A. Pattern recognition by pentraxins / A.Agrawal [et. al.] // Adv Exp. Med. Biol. – 2009. – Vol. 653. – P. 98-116.

Balbarini, A. Circulating endothelial progenitor cells characterization, function and relationship with cardiovascular risk factors / A. Balbarini [et. al.] // Curr. Pharm Des. – 2007. – Vol. 13. – № 16. – P. 1699-1713.

Ballou, S.P. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein / S.P. Ballow, G. Lozanski // Cytokine. – 1992. – Vol. 4. – № 5. – P. 361-368.

Black, S. The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct / S. Blak, A. Agrawal , D. Samols // Mol. Immunol. – 2003. – Vol. 39. – № 16. – P. 1045-1054.

Briles, D.E. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens / D.E. Briles [et. al.] // Infect. Immun. – 1989. – Vol.57. – № 5. – P. 1457-1464.

Brown, J.S. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice / J.S. Brown [et. al.] // Proc. Natl. Acad. Sci. U S A. – 2002. – Vol. 99. – № 26. – P. 16969-16974.

Calabro, P. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells / P.Calabro, J.T. Willerson, E.T. Yeh // Circulation. – 2003. – Vol. 108. – № 16. – P. 1930-1932.

Cals, J.W. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial / J.W. Cals [et. al.] // Ann. Fam. Med. – 2010. – Vol. 8. – № 2. – P. 124-133.

Carlucci, F. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis / F. Carlucci [et. al.] // Arthritis Rheum. – 2010. – Vol. 62. – №1. – P. 245-249.

Casas, J.P. Insight into the nature of the CRP-coronary event association using Mendelian randomization / J.P. Casas [et. al.] // Int. J. Epidemiol. – 2006. – Vol. 35. – № 4. – P. 922-931.

Chang, M.K. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids / M. K. Chang [et. al.] // Proc. Natl. Acad. Sci. U S A. – 2002. – Vol. 99. – № 20. – P. 13043-13048.

Chen, J.Z. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood / J. Z. Chen [et. al.] // J. Mol. Cell. Cardiol. – 2004. – Vol. 36. – № 2. – P. 233-239.

Cirillo, P. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation / P.Cirillo [et. al.] // Cardiovasc. Res. – 2005. – Vol. 68. – № 1. – P. 47-55.

Ciubotaru, I. Production of modified C-reactive protein in U937-derived macrophages / I. Ciubotaru, L. A. Potempa, R.C.Wander // Exp. Biol. Med. (Maywood). – 2005. – Vol. 230. – № 10. – P. 762-770.

Clapp, B.R. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability / B.R. Clapp [et. al.] // Circulation. – 2005. – Vol. 111. – № 12. – P. 1530-1536.

Dahl, M. Genetic and biochemical markers of obstructive lung disease in the general population / M. Dahl // Clin. Respir. J. – 2009. – Vol. 3. – № 2. – P. 121-122.

Danenberg, H.D. Neointimal formation is reduced after arterial injury in human crp transgenic mice / H.D. Danenberg [et. al.] // Atherosclerosis. – 2008. – Vol. 201. – № 1. – P. 85-91.

Danesh, J. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review / J. Danesh [et. al.] // PLoS Med. – 2008. – Vol. 5. – № 4. – P.78.

De Luis, D.A. Influence of Ala54Thr polymorphism of fatty acid-binding protein 2 on insulin resistance and adipocytokines in patients with diabetes mellitus type 2 / D.A. De Luis [et. al.] // Eur. Rev. Med. Pharmacol. Sci. – 2010. – Vol. 14. – № 2. – P. 89-95.

Dela Paz, N.G. Regulation of NF-kappaB-dependent gene expression by the POU domain transcription factor Oct-1 / N. G. Dela Paz [et. al.] // J. Biol. Chem. – 2007. – Vol. 282. – № 11. – P. 8424-8434.

Delhaye, C. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation / C. Delhaye [et. al.] // Am. J. Cardiol. – 2010. – Vol. 105. – № 6. – P. 826-832.

Deshmane, S.L. Monocyte chemoattractant protein-1 (MCP-1): an overview / S.L. Deshmane [et. al.] // J. Interferon. Cytokine. Res. – 2009. – Vol. 29. – № 6. – P. 313-326.

Devaraj, S. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions / S. Devaraj [et. al.] // Am. J. Physiol. Heart. Circ. Physiol. – 2006. – Vol. 291. – № 3. – P.1170-1176.

Devaraj, S. The evolving role of C-reactive protein in atherothrombosis / S. Devaraj , U.Singh , I.Jialal // Clin. Chem. – 2009. – Vol. 55. – № 2. – P. 229-238.

Dong, Q. Expression of C-reactive protein by alveolar macrophages / Q. Dong, J.R. Wright // J. Immunol. – 1996. – Vol. 156. – № 12. – P. 4815-4820.

Durand, M.L. Acute bacterial meningitis in adults / M.L. Durand [et. al.] // N. Engl. J. Med. – 1993. – Vol. 328. – № 1. – P. 21-28.

Eisenhardt, S.U. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques / S.U. Eisenhardt [et. al.] // Circ. Res. – 2009. – Vol. 105. – № 2. – P. 128-137.

Eisenhardt, S.U. C-reactive protein: how conformational changes influence inflammatory properties / S.U. Eisenhardt [et. al.] // Cell Cycle. – 2009. – Vol. 8. – № 23. – P. 3885-3892.

Frey, R.S. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology / R.S. Frey, M. Ushio-Fukai, A.B. Malik // Antioxid. Redox. Signal. – 2009. – Vol. 11. – № 4. – P.791-810.

Fujii, H. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells / H. Fujii [et. al.] // Arterioscler. Thromb. Vasc. Biol. – 2006. – Vol. 26. – № 11. – P. 2476-2482.

Garlanda, C. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response / C. Garlanda [et. al.] // Nature. – 2002. – Vol. 420. –№ 6912. – P. 182-186.

Gershov, D. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity / D. Gershov [et. al.] // J. Exp. Med. – 2000. – Vol. 192. – № 9. – P. 1353-1364.

Ghose, T. Oswald Avery: the professor, DNA, and the Nobel Prize that eluded him / T. Ghose // Can. Bull. Med. Hist. – 2004. – Vol. 21. – № 1. – P. 135-144.

Gill, R. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats / R. Gill [et. al.] // J. Cereb. Blood. Flow. Metab. – 2004. – Vol. 24. – № 11. – P.1214-1218.

Griselli, M. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction / M. Griselli [et. al.] // J. Exp. Med. – 1999. – Vol. 190. – № 12. – P. 1733-1740.

Hakobyan, S. Complement factor H binds to denatured rather than to native pentameric C-reactive protein / S. Hakobyan [et. al.] // J. Biol. Chem. – 2008. – Vol. 283. – № 45. – P. 30451-30460.

Hans, C.P. Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats / C.P. Hans, D.P. Chaudhary, D.D. Bansal // Magnes Res. – 2003. – Vol. 16. – № 1. – P. 13-19.

Hattori, Y. Vascular smooth muscle cell activation by C-reactive protein / Y. Hattori, M. Matsumura, K. Kasai // Cardiovasc Res. – 2003. – Vol. 58. – №1. – P. 186-195.

Heslop, C.L. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography / C.L. Heslop, J.J. Frohlich, J.S. Hill // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – № 11. – P. 1102-1109.

Jennings, H.J. Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1 / H.J. Jennings, C. Lugowski, N.M. Young // Biochemistry. – 1980. –Vol. 19. –№ 20. – P. 4712-4719.

Ji, S.R. C-reactive protein activates endothelial cells via interaction with lipid raft microdomains / S.R. Ji [et. al.] // FASEB J. – 2009. – Vol. 23. – № 6. – P. 1806-1816.

Ji, S.R. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions / S.R. Ji [et. al.] // Arterioscler. Thromb. Vasc. Biol. – 2006. – Vol. 26. – № 4. – P. 935-941.

Ji, S.R. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m) / S.R. Ji [et. al.] // FASEB J. – 2007. – Vol. 21. –№1. – P.284-294.

Jialal, I. C-reactive protein: risk marker or mediator in atherothrombosis / I. Jialal, S. Devaraj, S.K. Venugopal // Hypertension. – 2004. – Vol. 44. – № 1. – P. 6-11.

Kerr, A.R. Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3 / A.R. Kerr [et. al.] // Infect. Immun. 2005. – Vol. 73. – № 7. – P. 4245-4252.

Khreiss, T. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils / T. Khreiss [et. al.] // J. Biol. Chem. – 2002. – Vol. 277. – № 43. – P. 40775-40781.

Khreiss, T. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells / T. Khreiss [et. al.] // Circulation. – 2004. – Vol. 109. – №16. – P.2016-2022.

King, D.E. Magnesium intake and serum C-reactive protein levels in children / D.E. King [et. al.] // Magnes. Res. – 2007. – Vol. 20. – №1. – P.32-36.

King, D.E. Dietary magnesium and C-reactive protein levels / D.E. King [et. al.] // J. Am. Coll. Nutr. – 2005. – Vol. 24. – P. 166–171.

Kinoshita, C.M. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein / C.M. Kinoshita [et. al.] // Biochemistry. – 1989. – Vol. 28. – № 25. – P. 9840-9848.

Kleemann, R. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro / R. Kleemann [et. al.] // Blood. – 2004. – Vol. 103. – № 11. – P. 4188-4194.

Koike, T. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits / T. Koike [et. al.] // Circulation. – 2009. – Vol. 120. – № 21. – P. 2088-2094.

Kottgen, E. Lectin specificity and binding characteristics of human C-reactive protein / E. Kottgen [et. al.] // J. Immunol. – 1992. – Vol. 149. – № 2. – P. 445-453.

Kovacs, A. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia / A. Kovacs [et. al.] // Proc. Natl. Acad. Sci. U S A. – 2007. – Vol. 104. – № 34. – P.13768-73.

Kresl, J.J. Inhibition of mouse mammary adenocarcinoma (EMT6) growth and metastases in mice by a modified form of C-reactive protein / J.J. Kresl [et. al.] // Tumour Biol. – 1999. – Vol. 20. – № 2 – P. 72-87.

Kuller, L.H. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial / L.H. Killer [et. al.] // Am. J. Epidemiol. – 1996. – Vol. 144. – № 6. – P.537-47.

Kushner, I. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1 / I. Kushner [et. al.] // Ann. N. Y. Acad. Sci. – 1995. – Vol. 762. – P. 102-107.

Lavi, S. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans / S. Lavi [et. al.] // Circulation. – 2007. – Vol. 115. – № 21. – P. 2715-2721.

Lee, R.T. Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide / R.T. Lee, Y.C. Lee // Glycoconj J. – 2006. – Vol. 23. – № 5-6. – P. 317-327.

Li, J.J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide / J.J. Li, X.J. Chen // Coron. Artery. Dis. – 2003. – Vol. 14. – № 4. – P. 329-334.

Li, L. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction / L. Li [et. al.] // Circ Res. – 2004. – Vol. 95. – № 9. – P. 877-883.

Li, S.H. C-reactive protein upregulates complement-inhibitory factors in endothelial cells / S.H. Li [et. al.] // Circulation. – 2004. – Vol. 109. – № 7. – P. 833-836.

Lim, W.S. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines / W.S. Lim [et. al.] // Thorax. – 2001. – Vol. 56. – № 4. – P. 296-301.

Lin, Y.J. Prognostic Implications of the High-Sensitive C-Reactive Protein in the Catheter Ablation of Atrial Fibrillation / Y.J. Lin [et. al.] // Am. J. Cardiol. – 2010. – Vol. 105. – № 4. – P. 495-501.

Liu, Y. CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection / Y. Liu, M.R. Nonnemacher, B. Wigdahl // Future. Microbiol. – 2009. – № 4. – P. 299-321.

Liuzzo, G. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation / G. Luizzo [et. al.] // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – № 2. – P. 185-194.

Magnusson, M.K. Fibronectin: structure, assembly, and cardiovascular implications / M.K. Magnusson, D.F. Mosher //Arterioscler. Thromb. Vasc. Biol. – 1998. – Vol.18. – № 9. – P. 1363-1370.

Miyazawa, K. Complement activation induced by human C-reactive protein in mildly acidic conditions / K. Miyazawa, K. Inoue // J Immunol. – 1990. – Vol. 145. – № 2. – P. 650-654.

Mold, C. Regulation of complement activation by C-reactive protein / C. Mold, H. Gewurz, T.W. Du Clos // Immunopharmacology. – 1999. – Vol. 42. – № 1-3. – P. 23-30.

Mold, C. Binding of human C-reactive protein to bacteria / C. Mold [et. al.] // Infect. Immun. – 1982. – Vol. 38. – №1. – P. 392-395.

Mold, C. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R / C. Mold [et. al.] // J. Immunol. – 2002. – Vol .169. – № 12. – P. 7019-7025.

Mortensen, R.F. Regulation of phagocytic leukocyte activities by C-reactive protein / R.F. Mortensen, W. Zhong // J. Leukoc. Biol. – 2000. – Vol. 67. – № 4. – P. 495-500.

Nagaoka, T. C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production / T. Nagaoka [et. al.] // Invest. Ophthalmol. Vis. Sci. – 2008. – Vol. 49. – № 5. – P. 2053-2060.

Ng, P.M. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria / P.M. Ng [et. al.] // EMBO J. – 2007. – Vol. 26. – № 14. – P. 3431-3440.

Oei, H.H. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study / H.H. Oei [et. al.] // Circulation. – 2005. – Vol. 111. – № 5. – P. 570-575.

Ouchi, N. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue / N. Ouchi [et. al.] // Circulation. – 2003. – Vol. 107. – № 5. – P. 671-674.

Pasceri, V. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs / V. Pasceri [et. al.] // Circulation. – 2001. – Vol. 103. – № 21. – P. 2531-2534.

Pasceri, V. Direct proinflammatory effect of C-reactive protein on human endothelial cells / V. Pasceri, J.T. Willerson, E.T. Yeh // Circulation. – 2000. – Vol. 102. – № 18. – P. 2165-2168.

Pearson, T.A. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association / T.A. Pearson [et. al.] // Circulation. – 2003. – Vol. 107. – № 3. – P. 499-511.

Pepys, M.B. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself / M.B. Pepys [et. al.] // Circ. Res. – 2005. – Vol. 97. – № 11. – P.97-103.

Pepys, M.B. Targeting C-reactive protein for the treatment of cardiovascular disease / M.B. Pepys [et. al.] // Nature. – 2006. – Vol. 440. – № 7088. – P. 1217-1221.

Pepys, M.B. C-reactive protein: binding to lipids and lipoproteins / M.B. Pepys, I.F. Rowe, M.L. Baltz // Int. Rev. Exp. Pathol. – 1985. – Vol. 27. – P. 83-111.

Phillips, K. The virtuoso of versatility: POU proteins that flex to fit / K. Phillips, B. Luisi // J. Mol. Biol. – 2000. – Vol. 302. – № 5. – P. 1023-1039.

Pompilio, G. Endothelial progenitor cells and cardiovascular homeostasis: clinical implications / G. Pompilio [et. al.] // Int. J. Cardiol. – 2009. – Vol. 131. – № 2. – P. 156-167.

Potempa, L.A. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium / L.A. Potempa [et. al.] // Mol. Immunol. – 1983. – Vol. 20. – № 11. – P. 1165-1175.

Potempa, L.A. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit / L.A. Potempa [et. al.] // Mol. Immunol. – 1987. – Vol. 24. – № 5. – P. 531-541.

Qamirani, E. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase / E. Qamirani [et. al.] // Arterioscler. Thromb. Vasc. Biol. – 2005. – Vol. 25. – № 5. – P.995-1001.

Ramadan, M.A. The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals / M.A. Ramadan [et. al.] // Acta. Crystallogr. D. Biol. Crystallogr. – 2002. – Vol. 58. – Pt 6. – Pt 2. – P. 992-1001.

Roozendaal, R. Emerging patterns in complement-mediated pathogen recognition / R. Roozendaal, M.C. Carroll // Cell. – 2006. – Vol. 125. – № 1. – P. 29-32.

Schroecksnadel, K. Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers / K. Schroecksnadel [et. al.] // Thromb. Haemost. – 2010. – Vol. 103. – № 5.

Schwartz, R. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice / R.Schwartz [et. al.] // Circ. Res. – 2007. – Vol. 100. – № 10. – P. 1452-1459.

Shine, B. Solid phase radioimmunoassays for human C-reactive protein / B. Shine, F.C. de Beer, M.B. Pepys // Clin. Chim. Acta. – 1981. – Vol. 117. – № 1. – P.3-23.

Shrive, A.K. Three dimensional structure of human C-reactive protein / A.K. Shrive [et. al.] // Nat. Struct. Biol. – 1996. – Vol. 3. – № 4. – P. 346-54.

Sierra, R. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome / R. Sierra [et. al.] // Intensive Care Med. – 2004. – Vol. 30. – № 11. – P. 2038-2045.

Simental-Mendia, L.E. Failure of beta-cell function for compensate variation in insulin sensitivity in hypomagnesemic subjects / L.E. Simental-Mendia, M. Rodriguez-Moran , F. Guerrero-Romero // Magnes. Res. – 2009. – Vol. 22. – № 3. – P.151-156.

Singh, P.P. Serum amyloid P-component in murine tuberculosis: induction kinetics and intramacrophage Mycobacterium tuberculosis growth inhibition in vitro / P.P. Singh, S. Kaur // Microbes. Infect. – 2006. – Vol. 8. – № 2. – P. 541-551.

Singh, P.P. A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter / P.P. Singh, B. Voleti, A. Agrawal // J. Immunol. – 2007. – Vol. 178. – № 11. – P. 7302-7309.

Singh, U. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats / U. Singh [et. al.] // J. Lipid. Res. – 2008. – Vol. 49. – № 5. – P. 1015-1023.

Singh, U. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production / U. Singh [et. al.] // Arterioscler. Thromb. Vasc. Biol. – 2006. – Vol.26. – № 11. – P. 2469-2475.

Singh, U. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes / U. Singh, S. Devaraj, I. Jialal // Clin. Chem. – 2009. – Vol. 55. – № 2. – P. 361-364.

Singh, U. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling / U. Singh [et. al.] // J. Mol. Cell. Cardiol. – 2007. – Vol. 43. – № 6. – P. 780-791.

Song Y. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women / Y. Song [et. al.] // Am. J. Clin. Nutr. – 2007. – Vol. 85. – № 4. – P. 1068-1074.

Suresh, M.V. Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications / M.V. Suresh, S.K. Singh, A. Agrawal // J. Biol. Chem. – 2004. – Vol. 279. – № 50. – P. 52552-52557.

Suresh, M.V. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide / M.V. Suresh [et. al.] // J. Immunol. – 2007. – Vol. 178. – № 2. – P. 1158-1163.

Suresh, M.V. Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection / M.V. Suresh [et. al.] // J. Immunol. – 2006. – Vol. 176. – № 7. –P. 4369-4343.

Szalai, A.J. C-reactive protein: structural biology and host defense function / A.J. Szalai [et. al.] // Clin. Chem. Lab. Med. – 1999. – Vol. 37. – № 3. – P. 265-270.

Szalai, A.J. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein / A.J. Szalai [et. al.] // J Immunol. – 2002. – Vol. 168. – № 11. – P. 5792-5797.

Szalai, A.J. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice / A.J. Szalai [et. al.] // Infect Immun. – 2000. – Vol. 68. – № 10. – P. 5652-5656.

Szalai, A.J. The antimicrobial activity of C-reactive protein / A.J. Szalai // Microbes. Infect. – 2002. – Vol.4. – № 2. – P. 201-205.

Talmadge, J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy/ J.E. Talmadge // Clin Cancer Res. – 2007. – Vol. 13 – № 18. – Pt 1. – P. 5243-5238.

Taylor, K.E. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide / K.E. Taylor, J.C. Giddings, C.W. van den Berg // Arterioscler. Thromb. Vasc. Biol. – 2005. – Vol. 25. – № 6. – P. 1225-1230.

Tennent, G.A. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice / G.A. Tennent [et. al.] // Atherosclerosis. – 2008. – Vol. 196. – № 1. – P. 248-255.

Teoh, H. Impaired endothelial function in C-reactive protein overexpressing mice / H. Teoh [et. al.] // Atherosclerosis. – 2008. – Vol. 201. – № 2. – P.318-325.

Thompson, D. The physiological structure of human C-reactive protein and its complex with phosphocholine / D. Thompson, M.B. Pepys, S.P. Wood // Structure. – 1999. – Vol. 7. – № 2. – P. 169-177.

Tilg, H. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells / H.Tilg [et. al.] // J. Exp. Med. – 1993. – Vol. 178. – № 5. – P. 1629-1936.

UstUn, Y. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia / Y. UstUn [et. al.] // J Matern Fetal Neonatal Med. – 2010. – Vol. 23. – № 4 – P. 311-314.

Van den Berg, C.W. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations / C.W. van den Berg, K.E. Taylor, D. Lang // Arterioscler. Thromb. Vasc. Biol. – 2004. – Vol. 24. – № 10. – P. 168-171.

Venugopal, S.K. C-reactive protein decreases prostacyclin release from human aortic endothelial cells / S.K Venugopal, S. Devaraj, I. Jialal // Circulation. – 2003. – Vol. 108. – № 141. – P.676-1678.

Venugopal, S.K. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects / S.K Venugopal, S. Devaraj, I. Jialal // Am. J. Pathol. – 2005. – Vol. 166. – № 4. – P.1265-1271.

Vigushin, D.M. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease / D.M. Vigushin, M.B. Pepys, P.N. Hawkins // J. Clin. Invest. – 1993. – Vol. 91. – № 4. – P. 1351-1357.

Voleti, B. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter / B. Voleti, A. Agrawal // J. Immunol. – 2005. – Vol. 175. – № 5. – P. 3386-3390.

Walport, M.J. Complement. First of two parts / M.J. Walport // N. Engl. J. Med. – 2001. –Vol. 344. – № 14. – P. 1058-1066.

Walport, M.J. Complement. Second of two parts / M.J. Walport // N. Engl. J. Med. – 2001. – Vol. 344. – №15. – P. 1140-1144.

Weis, W.I. Trimeric structure of a C-type mannose-binding protein / W.I. Weis, K. Drickamer // Structure. – 1994. – Vol. 2. – № 12. – P. 1227-1240.

Werner, N. Circulating endothelial progenitor cells and cardiovascular outcomes / N. Werner [et. al.] // N. Engl. J. Med. – 2005. – Vol. 353. – № 10. – P. 999-1007.

Williams, T.N. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization / T.N. Williams [et. al.] // Arterioscler. Thromb. Vasc. Biol. – 2004. – Vol. 24. – № 1. – P. 61-66.

Xing, D. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent / D. Xing [et. al.] // Am. J. Pathol. – 2008. – Vol. 172. – № 1. – P. 22-30.

Yilmaz, F.M. Nitric oxide, lipid peroxidation and total thiol levels in acute appendicitis / F.M. Yilmaz [et. al.] // J. Clin. Lab. Anal. – 2010. – Vol. 24. – № 2. – P. 63-66.

Yuste, J. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumonia / J. Yuste [et. al.] // PLoS Pathog. – 2007. – Vol. 3. – № 9. – P. 1208-1219.

Zacharakis, M. Predictors of survival in stage IV metastatic colorectal cancer / M. Zacharakis [et. al.] // Anticancer Res. – 2010. – Vol. 30. – № 2. – P. 653-660.

Zacho, J. Genetically elevated C-reactive protein and ischemic vascular disease / J. Zacho [et. al.] //N. Engl. J. Med. – 2008. – Vol. 359. – № 18. – P. 1897-1908.

Zhang, R. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease / R. Zhang [et. al.] // Hypertension. – 2010. – Vol. 55. – №4. – P. 953-60.

Zouki, C. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion / C. Zouki [et. al.] // J. Immunol. – 2001. – Vol. 167. – № 9. – P. 5355-5361.


Ссылки

  • На текущий момент ссылки отсутствуют.